Millennium Management LLC Buys 333,167 Shares of Immunocore Holdings plc (NASDAQ:IMCR)

Millennium Management LLC boosted its holdings in Immunocore Holdings plc (NASDAQ:IMCR) by 124.4% in the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 600,954 shares of the company’s stock after buying an additional 333,167 shares during the quarter. Millennium Management LLC’s holdings in Immunocore were worth $20,366,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in IMCR. NEOS Investment Management LLC bought a new stake in shares of Immunocore during the 4th quarter valued at $262,000. Tidal Investments LLC bought a new position in shares of Immunocore during the 1st quarter valued at about $423,000. China Universal Asset Management Co. Ltd. boosted its stake in Immunocore by 69.8% during the first quarter. China Universal Asset Management Co. Ltd. now owns 6,621 shares of the company’s stock valued at $430,000 after buying an additional 2,721 shares during the last quarter. Nan Fung Group Holdings Ltd purchased a new position in shares of Immunocore in the first quarter valued at $439,000. Finally, DNB Asset Management AS increased its holdings in shares of Immunocore by 35.0% in the 2nd quarter. DNB Asset Management AS now owns 7,211 shares of the company’s stock worth $244,000 after buying an additional 1,868 shares during the last quarter. Institutional investors own 84.50% of the company’s stock.

Immunocore Stock Up 2.0 %

Shares of IMCR stock opened at $31.11 on Friday. The business’s fifty day moving average is $35.25 and its 200-day moving average is $44.55. The stock has a market cap of $1.56 billion, a PE ratio of -25.50 and a beta of 0.72. Immunocore Holdings plc has a 1 year low of $29.72 and a 1 year high of $76.98. The company has a debt-to-equity ratio of 1.31, a quick ratio of 5.15 and a current ratio of 5.17.

Immunocore (NASDAQ:IMCR) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.23) EPS for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.25. The company had revenue of $75.40 million during the quarter, compared to analyst estimates of $74.58 million. Immunocore had a negative net margin of 19.16% and a negative return on equity of 14.68%. The business’s quarterly revenue was up 26.2% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.37) earnings per share. Equities analysts expect that Immunocore Holdings plc will post -1.79 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms recently commented on IMCR. Oppenheimer reaffirmed an “outperform” rating and issued a $89.00 price target (up previously from $87.00) on shares of Immunocore in a research note on Friday, August 9th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Immunocore in a research report on Monday, September 9th. HC Wainwright reiterated a “buy” rating and issued a $100.00 target price on shares of Immunocore in a research report on Tuesday, September 17th. Barclays decreased their price objective on Immunocore from $92.00 to $66.00 and set an “overweight” rating on the stock in a report on Friday, August 9th. Finally, JPMorgan Chase & Co. cut their price target on shares of Immunocore from $70.00 to $66.00 and set an “overweight” rating for the company in a report on Wednesday, July 10th. One investment analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $80.40.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.